{
    "clinical_study": {
        "@rank": "151477", 
        "acronym": "NIFEPAR_PK1", 
        "arm_group": [
            {
                "arm_group_label": "Nifedipine oral solution", 
                "arm_group_type": "Experimental", 
                "description": "Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose"
            }, 
            {
                "arm_group_label": "Nifedipine soft gelatine capsules", 
                "arm_group_type": "Active Comparator", 
                "description": "Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase I, crossover, randomised,  single dose, relative bioavailability clinical trial of a\n      new oral solution of nifedipine compared to Adalat soft gelatine capsules in healthy female\n      volunteers."
        }, 
        "brief_title": "Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Bioequivalence", 
        "detailed_description": {
            "textblock": "The study was designed to compare the bioavailability of nifedipine new formulation\n      specially designed to be used in pre-term labour management instead of anti-hypertensive\n      therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged 18 to 45.\n\n          -  Body weight within the normal range (Quetelet index between 19 and 26) expressed as\n             weight (kg) / height (m2) .\n\n          -  Medical history , physical examination within normal appliances .\n\n          -  No evidence of significant organic or psychiatric disease based on history, physical\n             examination and laboratory tests .\n\n          -  Laboratory tests (hematology and biochemistry) within the normal range , according to\n             normal reference values of the Biochemistry laboratory  of Hospital de la Santa Creu\n             i Sant Pau. Variations may be allowed based on clinical judgment of the Centre d'\n             Investigacio Medicament (CIM ) .\n\n          -  Vital signs: blood pressure (Systolic Blood Pressure (SBP) > 90 <140 mm Hg /\n             Diastolic Blood Pressure (DBP) > 50 <90 mm \u200b\u200bHg ), heart rate (> 50 <90 ) ,\n             temperature and ECG record within normal range.\n\n          -  Not having participated in another clinical trial during the previous three months at\n             the beginning of the current study .\n\n          -  Not having donated blood in the previous four weeks.\n\n          -  Free acceptance to participate in the trial. Written informed consent signed.\n\n          -  Use of effective contraception different from oral contraceptives.\n\n        Exclusion Criteria:\n\n          -  Previous history of alcohol or drug use or abuse during the previous month to the\n             selection process.\n\n          -  High consumption of stimulant beverages (> 5 coffee, tea, cola drinks daily).\n\n          -  Previous history of allergy, drug hypersensitivity or idiosyncrasy.\n\n          -  Taking any medication in the 4 weeks preceding the trial, including non-prescription\n             medicines and herbal remedies.\n\n          -  Positive serology for hepatitis B, C or HIV.\n\n          -  History or clinical evidence of cardiovascular disease, respiratory, renal, hepatic,\n             endocrine, gastrointestinal, hematological, neurological or other chronic diseases.\n\n          -  Having had surgery during the previous 6 months.\n\n          -  Having donated blood in the month before the study began.\n\n          -  Smokers.\n\n          -  Positive pregnancy test at any monitoring during the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071589", 
            "org_study_id": "2006-006159-11", 
            "secondary_id": "CIM/06/300/04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nifedipine soft gelatine capsules", 
                "description": "3 Adalat capsules of 10 mg each one", 
                "intervention_name": "Nifedipine soft gelatine capsules", 
                "intervention_type": "Drug", 
                "other_name": "Adalat"
            }, 
            {
                "arm_group_label": "Nifedipine oral solution", 
                "description": "6 mL of Nife Par solution", 
                "intervention_name": "Nifedipine oral solution", 
                "intervention_type": "Drug", 
                "other_name": "Nife-Par"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nifedipine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08025"
                }, 
                "name": "CIM Sant Pau"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Crossover Randomised Bioavailability Clinical Study Of A Single Dose Of Nifedipine Oral Solution From Laboratorio Reig Jofre S.A. Compared To Adalat(R) Capsules In Healthy Female Volunteers", 
        "overall_official": {
            "affiliation": "CIM Sant Pau", 
            "last_name": "Rosa M Antonijoan, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-Time Curve (AUC 0-24h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose"
            }, 
            {
                "measure": "Maximal plasmatic concentrations, Cmax", 
                "safety_issue": "No", 
                "time_frame": "pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to maximal plasmatic concentrations, Tmax", 
            "safety_issue": "No", 
            "time_frame": "pre-dose and +10', +20', +30', +45', +1h, +1h15', +1h30', +2h, +3h, +5h, +7h, +9h, +12h y +24h post dose"
        }, 
        "source": "Reig Jofre Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reig Jofre Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}